Using age-based subgroup data from a randomised Phase-3 clinical trial , nab-PC and sb-PC were compared with respect to overall response rate ( ORR ) , overall survival ( OS ) , progression-free survival ( PFS ) , quality of life ( QoL ) , safety/toxicity , and quality-adjusted time without symptoms or toxicity ( Q-TWiST ) with ages 60 and 70 years as cut points .